Navigation Links
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Date:10/31/2011

f the launch of EXPAREL.
  • As of September 30, 2011, Pacira had unrestricted cash, cash equivalents and short term investments of $37.1 million compared with $26.1 million on December 31, 2010.
  • Cash used in operating activities and for the purchase of fixed assets used in investing activities ("cash burn") was approximately $27 million for the nine months ended September 30, 2011.  

  • Full Year 2011 Financial Guidance

  • Pacira is reiterating its revenue expectations for 2011 and currently expects to achieve revenue in the range of $14 to $16 million for the full-year ending December 31, 2011.  This revenue expectation excludes the impact of potential sales of EXPAREL.
  • Pacira is also reiterating that its expectation for cash burn for the fourth quarter of 2011 is approximately $15 million. This cash burn expectation includes a $2 million development milestone due from Novo Nordisk A/S under the agreement announced in January 2011.  As a result, Pacira expects to exit 2011 with approximately $22 million in unrestricted cash, cash equivalents and short-term investments.

  • Upcoming ActivitiesPacira expects to present at the following investor conferences:

  • 2011 Brean Murray, Carret & Co. Life Sciences Summit, November 14, in New York
  • 23rd Annual Piper Jaffray Healthcare Conference, November 29-30, in New York

  • Pacira expects to have a presence at the following medical meetings:

  • American College of Toxicology (ACT), November 6-9, in New York
  • American Society of Health-System Pharmacists (ASHP), December 4-8, in New Orleans
  • Postgraduate Assembly in Anesthesiology (PGA), New York State Society of Anesthesiologists (NYSSA), December 9-13, in New York
  • New York School of Regional Anesthesia (NYSORA), December 17-18, in New York

  • Today's Conference Call and Webcast ReminderThe Pacira management team will host a conference call di
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
    (Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
    (Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
    Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
    ... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
    ... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
    Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
    (Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
    (Date:8/21/2014)... 21, 2014 American Addiction Centers, a ... for individuals with drug and/or alcohol addiction, has been ... Growing Private Companies. , The company is ranked 7th ... list and 4th on the list in the “Nashville ... of 995%, American Addiction Centers (AAC) ascended to number ...
    (Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Using two types ... the disease and may boost efforts to eradicate polio, ... 1,000 children in India found that giving the Salk ... been given the Sabin live-attenuated oral poliovirus vaccine (OPV) ... causes polio. The findings, reported in the Aug. ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 Pleio, ... adherence, is launching a new suite of services ... offerings assist retail pharmacy by applying proven behavior ... classes, resulting in increased medication adherence, higher PDC ... As such, Pleio’s PDC-targeted offerings align retail’s desire ...
    (Date:8/21/2014)... developed a way to use a laser to measure ... the laser system to a portable size, the technique ... themselves to draw blood. , "We are working hard ... to use in their daily lives," said Claire Gmachl, ... project,s senior researcher. "With this work we hope to ...
    Breaking Medicine News(10 mins):Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 3
    ... obese men because the telltale blood marker used to detect ... population, according to a new study led by Duke Prostate ... their bodies than normal weight men, and as a result, ... -- the gold standard for detecting prostate cancer -- can ...
    ... The extra blood volume produced in the obese may so ... the popular PSA test may be essentially useless for diagnosing ... in The Journal of the American Medical Association suggests. ... 13,000 prostate cancer patients at The Johns Hopkins Hospital and ...
    ... first reliable follow-up for patients after treatment, researchers ... Whole-body positron emission tomography (PET) scans three months ... help determine whether they,re cancer-free or require further ... difficult to determine if treatment has eliminated cervical ...
    ... survival of very sick children, study finds , , TUESDAY, ... team of experts at a children,s hospital can cut ... outside the intensive care unit, a new study suggests. ... improvement in mortality, so that adds to the potential ...
    ... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
    ... Kelle Ilitch, an,entrepreneur trained in Pilates, is bringing the ... boutique, Pure Element Pilates.,Ilitch,s version of the innovative barre ... weights, Pilates and dance exercises,in rapid sequence to tone ... available at any other studios in the area. ...
    Cached Medicine News:Health News:Study suggests adjusting PSA scores for obese men or cancers may be missed 2Health News:Obesity-linked high blood volumes render PSA prostate cancer test less effective, study suggests 2Health News:PET Scans Can Spot Cervical Cancer's Return 2Health News:Rapid Response Teams Can Save Hospitalized Kids 2Health News:Rapid Response Teams Can Save Hospitalized Kids 3Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3
    For the quantitative in vitro determination of Cholesterol in serum and plasma....
    For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
    The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
    The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
    Medicine Products: